{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T10:52:02Z","timestamp":1775818322478,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970208"],"award-info":[{"award-number":["81970208"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.taap.2023.116572","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T21:59:59Z","timestamp":1685656799000},"page":"116572","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Pristimerin protects against pathological cardiac hypertrophy through improvement of PPAR\u03b1 pathway"],"prefix":"10.1016","volume":"473","author":[{"given":"Ye","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoxiang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianhao","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingwei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaiping","family":"Jing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaxuan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"434","key":"10.1016\/j.taap.2023.116572_bb0005","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan4935","article-title":"Ablation of the stress protease OMA1 protects against heart failure in mice","volume":"10","author":"Acin-Perez","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.taap.2023.116572_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113950","article-title":"Pristimerin mediated anticancer effects and sensitization of human skin cancer cells through modulation of MAPK signaling pathways","volume":"156","author":"Al-Tamimi","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"6","key":"10.1016\/j.taap.2023.116572_bb0015","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jchf.2019.02.015","article-title":"Outcomes and effect of treatment according to etiology in HFrEF: an analysis of PARADIGM-HF","volume":"7","author":"Balmforth","year":"2019","journal-title":"JACC Heart Fail."},{"issue":"8","key":"10.1016\/j.taap.2023.116572_bb0020","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41569-018-0044-6","article-title":"Metabolic remodelling in heart failure","volume":"15","author":"Bertero","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.taap.2023.116572_bb0025","article-title":"Cellular and molecular mechanisms of pristimerin in cancer therapy: recent advances","volume":"11","author":"Chen","year":"2021","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.taap.2023.116572_bb0030","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.cmet.2020.12.003","article-title":"The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure","volume":"33","author":"Cluntun","year":"2021","journal-title":"Cell Metab."},{"issue":"16","key":"10.1016\/j.taap.2023.116572_bb0035","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1093\/eurheartj\/ehm296","article-title":"Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists","volume":"28","author":"Collins","year":"2007","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.taap.2023.116572_bb0040","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/978-3-319-55330-6_11","article-title":"Mitochondria and cardiac hypertrophy","volume":"982","author":"Facundo","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"issue":"1","key":"10.1016\/j.taap.2023.116572_bb0045","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11427-017-9197-5","article-title":"AMPK and cardiac remodelling","volume":"61","author":"Feng","year":"2018","journal-title":"Sci. China Life Sci."},{"issue":"1","key":"10.1016\/j.taap.2023.116572_bb0050","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1038\/s41467-023-37291-5","article-title":"A defect in mitochondrial protein translation influences mitonuclear communication in the heart","volume":"14","author":"Gao","year":"2023","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.taap.2023.116572_bb0055","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.taap.2023.116572_bb0060","first-page":"477","article-title":"Triterpenoid pristimerin induced HepG2 cells apoptosis through ROS-mediated mitochondrial dysfunction","volume":"18","author":"Guo","year":"2013","journal-title":"J. BUON"},{"issue":"1","key":"10.1016\/j.taap.2023.116572_bb0065","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41401-020-0401-y","article-title":"Puerarin ameliorated pressure overload-induced cardiac hypertrophy in ovariectomized rats through activation of the PPARalpha\/PGC-1 pathway","volume":"42","author":"Hou","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"issue":"3","key":"10.1016\/j.taap.2023.116572_bb0070","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1139\/bcb-2021-0251","article-title":"Pristimerin alleviates cigarette smoke-induced inflammation in chronic obstructive pulmonary disease via inhibiting NF-kappaB pathway","volume":"100","author":"Huang","year":"2022","journal-title":"Biochem. Cell Biol."},{"key":"10.1016\/j.taap.2023.116572_bb0075","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2147\/CIA.S380814","article-title":"The diagnostic value of the deepest S wave in 12-Lead electrocardiogram to elderly patients with essential hypertension and left ventricular hypertrophy","volume":"17","author":"Ji","year":"2022","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.taap.2023.116572_bb0080","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3389\/fphar.2019.00746","article-title":"Anti-cancer effects of pristimerin and the mechanisms: a critical review","volume":"10","author":"Li","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.taap.2023.116572_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106326","article-title":"Attenuation of pristimerin on TNF-alpha-induced endothelial inflammation","volume":"82","author":"Liang","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"6 Suppl 1","key":"10.1016\/j.taap.2023.116572_bb0090","first-page":"S84","article-title":"Pristimerin exerts antitumor activity against MDA-MB-231 triple-negative breast cancer cells by reversing of epithelial-mesenchymal transition via downregulation of integrin beta3","volume":"44","author":"Liu","year":"2021","journal-title":"Biom. J."},{"issue":"1","key":"10.1016\/j.taap.2023.116572_bb0095","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1152\/physrev.00015.2009","article-title":"Myocardial fatty acid metabolism in health and disease","volume":"90","author":"Lopaschuk","year":"2010","journal-title":"Physiol. Rev."},{"issue":"7","key":"10.1016\/j.taap.2023.116572_bb0100","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41569-018-0007-y","article-title":"Mechanisms of physiological and pathological cardiac hypertrophy","volume":"15","author":"Nakamura","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"issue":"5","key":"10.1016\/j.taap.2023.116572_bb0105","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.cmet.2011.10.001","article-title":"PPARalpha-Sirt1 complex mediates cardiac hypertrophy and failure through suppression of the ERR transcriptional pathway","volume":"14","author":"Oka","year":"2011","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.taap.2023.116572_bb0110","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12916-023-02794-x","article-title":"The association between menstrual cycle characteristics and cardiometabolic outcomes in later life: a retrospective matched cohort study of 704,743 women from the UK","volume":"21","author":"Okoth","year":"2023","journal-title":"BMC Med."},{"issue":"2","key":"10.1016\/j.taap.2023.116572_bb0115","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1139\/cjpp-2019-0566","article-title":"Mechanisms for the transition from physiological to pathological cardiac hypertrophy","volume":"98","author":"Oldfield","year":"2020","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.taap.2023.116572_bb0120","article-title":"Pristimerin suppresses RANKL-induced osteoclastogenesis and ameliorates ovariectomy-induced bone loss","volume":"11","author":"Qi","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.taap.2023.116572_bb0125","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1152\/physrev.00030.2020","article-title":"Obesity cardiomyopathy: evidence, mechanisms, and therapeutic implications","volume":"101","author":"Ren","year":"2021","journal-title":"Physiol. Rev."},{"issue":"2","key":"10.1016\/j.taap.2023.116572_bb0130","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1161\/CIRCRESAHA.119.315483","article-title":"Metabolic remodeling promotes cardiac hypertrophy by directing glucose to aspartate biosynthesis","volume":"126","author":"Ritterhoff","year":"2020","journal-title":"Circ. Res."},{"issue":"4","key":"10.1016\/j.taap.2023.116572_bb0135","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.yjmcc.2010.09.021","article-title":"The PGC-1 cascade as a therapeutic target for heart failure","volume":"51","author":"Schilling","year":"2011","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"4","key":"10.1016\/j.taap.2023.116572_bb0140","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1161\/CIRCHEARTFAILURE.110.959833","article-title":"Toll-like receptor-mediated inflammatory signaling reprograms cardiac energy metabolism by repressing peroxisome proliferator-activated receptor gamma coactivator-1 signaling","volume":"4","author":"Schilling","year":"2011","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.taap.2023.116572_bb0145","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.yjmcc.2016.06.001","article-title":"Physiological and pathological cardiac hypertrophy","volume":"97","author":"Shimizu","year":"2016","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"9","key":"10.1016\/j.taap.2023.116572_bb0150","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s00204-015-1477-x","article-title":"Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets","volume":"89","author":"Tham","year":"2015","journal-title":"Arch. Toxicol."},{"issue":"4","key":"10.1016\/j.taap.2023.116572_bb0155","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cbf.3335","article-title":"Pristimerin targeting NF-kappaB pathway inhibits proliferation, migration, and invasion in esophageal squamous cell carcinoma cells","volume":"36","author":"Tu","year":"2018","journal-title":"Cell Biochem. Funct."},{"issue":"1","key":"10.1016\/j.taap.2023.116572_bb0160","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.yexcr.2017.03.052","article-title":"The role of cardiac energy metabolism in cardiac hypertrophy and failure","volume":"360","author":"Tuomainen","year":"2017","journal-title":"Exp. Cell Res."},{"issue":"12","key":"10.1016\/j.taap.2023.116572_bb0165","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.jacc.2023.01.026","article-title":"Optimal prevention of cardiovascular diseases: the earlier the better","volume":"81","author":"Ventura","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.taap.2023.116572_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113575","article-title":"The multifaceted mechanisms of pristimerin in the treatment of tumors state-of-the-art","volume":"154","author":"Wang","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"5","key":"10.1016\/j.taap.2023.116572_bb0175","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/s41401-021-00743-z","article-title":"Cardiomyocyte peroxisome proliferator-activated receptor alpha is essential for energy metabolism and extracellular matrix homeostasis during pressure overload-induced cardiac remodeling","volume":"43","author":"Wang","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"issue":"8","key":"10.1016\/j.taap.2023.116572_bb0180","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1158\/1535-7163.MCT-05-0027","article-title":"Pristimerin induces caspase-dependent apoptosis in MDA-MB-231 cells via direct effects on mitochondria","volume":"4","author":"Wu","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.taap.2023.116572_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104359","article-title":"Diminished arachidonate 5-lipoxygenase perturbs phase separation and transcriptional response of Runx2 to reverse pathological ventricular remodeling","volume":"86","author":"Xie","year":"2022","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.taap.2023.116572_bb0190","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41392-023-01378-8","article-title":"Metabolic landscape in cardiac aging: insights into molecular biology and therapeutic implications","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.taap.2023.116572_bb0195","first-page":"1650","article-title":"Beneficial effect of pristimerin against the development of osteoporosis in ovariectomy-induced osteoporosis rats by the RANKL\/TRAF6\/NF-kappaB pathway","volume":"18","author":"Xu","year":"2022","journal-title":"Arch. Med. Sci."},{"issue":"1","key":"10.1016\/j.taap.2023.116572_bb0200","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1080\/13880209.2021.1981399","article-title":"Pristimerin inhibits neuronal inflammation and protects cognitive function in mice with sepsis-induced brain injuries by regulating PI3K\/Akt signalling","volume":"59","author":"Xue","year":"2021","journal-title":"Pharm. Biol."},{"issue":"11","key":"10.1016\/j.taap.2023.116572_bb0205","doi-asserted-by":"crossref","first-page":"6208","DOI":"10.1111\/jcmm.15249","article-title":"Pristimerin-induced uveal melanoma cell death via inhibiting PI3K\/Akt\/FoxO3a signalling pathway","volume":"24","author":"Yan","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.taap.2023.116572_bb0210","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41420-019-0208-0","article-title":"Pristimerin induces apoptosis and autophagy via activation of ROS\/ASK1\/JNK pathway in human breast cancer in vitro and in vivo","volume":"5","author":"Zhao","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.taap.2023.116572_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2019.114813","article-title":"Pristimerin suppresses colorectal cancer through inhibiting inflammatory responses and Wnt\/beta-catenin signaling","volume":"386","author":"Zhao","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"3","key":"10.1016\/j.taap.2023.116572_bb0220","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1111\/jcmm.14129","article-title":"Molecular biomarkers in cardiac hypertrophy","volume":"23","author":"Zhu","year":"2019","journal-title":"J. Cell. Mol. Med."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X23002119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X23002119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:01:23Z","timestamp":1758574883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X23002119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":44,"alternative-id":["S0041008X23002119"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2023.116572","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pristimerin protects against pathological cardiac hypertrophy through improvement of PPAR\u03b1 pathway","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2023.116572","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116572"}}